Total voting rights:BB Biotech AG:BB Biotech AG: Publication pursuant to §26a WpHG (the German Securities Trading Act)
(Thomson Reuters ONE) -
BB Biotech AG /
/
BB Biotech AG: Publication pursuant to §26a WpHG (the German Securities Trading
Act)
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Pursuant to article 26a WpHG, BB Biotech AG, Vordergasse 3, 8200 Schaffhausen,
Switzerland, hereby announces that the total voting rights at the end of March
2012 amounted to 14'762'250.
The new number of voting rights is effective as of March 1, 2012.
For further information please contact:
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht / Zurich
Thomas Egger, Tel. +41 44 267 67 00.
Company profile
BB Biotech invests in companies in the fast growing market of biotechnology and
is one of the world's largest investors in this sector with around CHF 1.2 bn in
assets under management. BB Biotech is listed in Switzerland, Germany and Italy.
Its investments are focused on listed companies that are developing and
commercializing novel medical treatments and cures. BB Biotech's investment
selection process is guided by the fundamental research and analysis of
physicians and molecular biologists. Its Board of Directors has many years of
experience in industry and science.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: BB Biotech AG via Thomson Reuters ONE
[HUG#1598208]
Unternehmensinformation / Kurzprofil:
Datum: 30.03.2012 - 17:36 Uhr
Sprache: Deutsch
News-ID 130539
Anzahl Zeichen: 1956
contact information:
Town:
Schaffhausen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 198 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Total voting rights:BB Biotech AG:BB Biotech AG: Publication pursuant to §26a WpHG (the German Securities Trading Act)"
steht unter der journalistisch-redaktionellen Verantwortung von
BB Biotech AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
